en · de · es · fr · pt
aod-9604-notes.peptides1126.com › Data › Background And Research Context — Practical Notes

Background And Research Context — Practical Notes

By Editorial Desk · published 2026-04-27 · last reviewed 2026-06-08 · Data

Everything below concerns metabolic research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-06-08. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Related pages on this site

Identity and Molecular Context

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Supporting material

Among his early discoveries related to hydrazine was that phenylhydrazine reacted with sugars to form substances which he named osazones, and which, being highly crystalline and readily formed, served to identify such carbohydrates more definitely than had been previously possible. Later, among other work, he is noted for the organic synthesis of D-(+)-glucose. He showed how to deduce the formulae of the 16 stereoisomeric glucoses, and prepared several stereoisomerides, helping to confirm the Le Bel–Van 't Hoff rule of the asymmetric carbon atom. In the field of enzymology, Fischer is known for his proposal of "the lock and key" model as a mechanism of substrate binding. Fischer was also instrumental in the discovery of barbiturates, a class of sedative drugs used for insomnia, epilepsy, anxiety, and anesthesia. Along with the physician Josef von Mering, he helped to launch the first barbiturate sedative, barbital, in 1904. He next carried out pioneering work on proteins. By the introduction of new methods, he succeeded in breaking down the complex albumins into amino acids and other nitrogenous compounds, the constitutions of most of which were known, and by bringing about the recombination of these units, he prepared synthetic peptides which approximated to the natural products. His research group synthesised the first free dipeptide (Glycine-Glycine) in 1901. By 1906 about 65 peptides of different chain length and amino acid composition had been made by his research group.

Genetic studies have implicated mutations in the Wnt signaling pathway a possible hereditary genetic contributor to the disease, and various somatic chromosomal abnormalities as a non-hereditary or partially hereditary contributing factor. In 2020, the World Health Organization reclassified Dupuytren's (termed palmar-type fibromatosis) as a specific type of tumor in the category of intermediate (locally aggressive) fibroblastic and myofibroblastic tumors. Initial treatment is typically with cortisone injected into the affected area, occupational therapy, and physical therapy. Among those who worsen, clostridial collagenase injections or surgery may be tried. Radiation therapy may be used to treat this condition. The Royal College of Radiologists (RCR) Faculty of Clinical Oncology concluded that radiotherapy is effective in early stage disease which has progressed within the last 6 to 12 months. The condition may recur at some time after treatment; it can then be treated again. It is easier to treat when the amount of finger bending is more mild. It was once believed that Dupuytren's most often occurred in white males over the age of 50 and was thought to be rare among Asians and Africans. It sometimes was called "Viking disease," since it was often recorded among those of Nordic descent. In Norway, about 30% of men over 60 years old have the condition, while in the United States about 5% of people are affected at some point in time. In the United Kingdom, about 20% of people over 65 have some form of the disease.

=== Osteoblasts === Osteoblasts are the major cellular component of bone. Osteoblasts arise from mesenchymal stem cells (MSC). MSC give rise to osteoblasts, adipocytes, and myocytes among other cell types. Osteoblast quantity is understood to be inversely proportional to that of marrow adipocytes which comprise marrow adipose tissue (MAT). Osteoblasts are found in large numbers in the periosteum, the thin connective tissue layer on the outside surface of bones, and in the endosteum. Normally, almost all of the bone matrix, in the air breathing vertebrates, is mineralized by the osteoblasts. Before the organic matrix is mineralized, it is called the osteoid. Osteoblasts buried in the matrix are called osteocytes. During bone formation, the surface layer of osteoblasts consists of cuboidal cells, called active osteoblasts. When the bone-forming unit is not actively synthesizing bone, the surface osteoblasts are flattened and are called inactive osteoblasts. Osteocytes remain alive and are connected by cell processes to a surface layer of osteoblasts. Osteocytes have important functions in skeletal maintenance.

Sources: en.wikipedia.org

Notes from published material

According to the Panel of Experts on Yemen established pursuant to Security Council resolution 2140, the Houthis have carried out a wide range of human rights violations, including violations of international humanitarian law and abuse of women and children. Children as young as 13 have been arrested for "indecent acts" for alleged homosexual orientation or "political cases" when their families do not comply with Houthi ideology or regulations. Minors share cells with adult prisoners, and according to unspecified reports that the Panel has deemed "credible", boys held in Al-Shahid Al-Ahmar police station in Sana'a are systematically raped. Aside from the Panel of Experts, London-based Arabic newspaper Asharq Al-Awsat alleges that the Houthis have revived slavery in Yemen.

== Diagnosis == The diagnosis of nipple pain in breastfeeding can be divided into three major parts: the measurement of pain intensity, a physical examination on the breastfeeding mother and the infant to identify the cause of pain and the study of the psychological impact of pain in the breastfeeding woman.

Rosanna Jeanne Reardon (born June 8, 1985), known professionally as Rosanna Pansino, is an American YouTuber, businesswoman, and television personality. She is known for hosting her baking series Nerdy Nummies on YouTube (2011–present). She has written two cookbooks and released homeware lines based on the show. She has won a Shorty Award and been nominated for five Streamy Awards for Nerdy Nummies. She was listed first on Forbes' Top Influencers: Food in 2017. Early on in her career, Pansino appeared in minor television roles and the reality series Scream Queens (2010); she later went on to star in the YouTube Premium series Escape the Night (2018–2019) and host the HBO Max series Baketopia (2021). She independently released her debut single "Perfect Together" in 2015.

This hypothesis was opposed by French palaeontologist Marcellin Boule, who authored several publications starting in 1908 describing the French Neanderthal specimen La Chapelle-aux-Saints 1 ("The Old Man") as a slouching, ape-like creature distantly related to modern man. Boule's ideas would define discussions of Neanderthals for some time. Boule suggested two different lineages existed in Ice Age Europe: a more evolved one descending from the British Piltdown Man (a hoax) to the French Grimaldi Man (a Cro-Magnon) which would culminate with modern Europeans; and a less evolved dead-end lineage leading from the German Heidelberg Man to Neanderthal Man. As the focus of human origins shifted from Europe to East Asia ("Out of Asia" hypothesis) by the 1930s and 40s with discoveries such as Java Man and Peking Man (as well as the marginalisation of Piltdown Man), the question of a "Neanderthal phase" in human evolution once again became a topic of discussion. The definition of "Neanderthal" expanded to include several anatomically variable specimens around the Old World. In the contextual debate between monogenism and polycentrism, some specimens were described as "progressive" Neanderthals which would evolve into some local subspecies of H. sapiens (polycentricism), while the "classic" Neanderthals of the Western European Würm glaciation would not. In the 1970s, with the formulation of cladistics and the consequent refinement of the anatomical definitions of species, this "global morphological pattern" fell apart.

Sources: en.wikipedia.org

Further detail

== Chemistry == PSK is a protein polysaccharide consisting of a beta-glucan β-1,4 main chain with β-1,3 and β-1,6 side chains. The approximate molecular weight of PSK is 100,000 Da, and the protein component is reported at the β-1,6 side chain. PSK is isolated from the "CM-101" strain of Trametes versicolor. The analogous compound PSP, is derived from the "COV-1" strain of Trametes versicolor.

The gene CALCA is notable for producing three distinct hormones with different effects. In addition to CGRP1, an alternative splicing encodes a precursor protein that is cleaved into calcitonin and katacalcin, which both function to reduce blood calcium levels. In addition to CGRP1, there is a second calcitonin gene-related peptide called CGRP2. This peptide is encoded by a separate gene, CALCB, but shares 90%+ homology (differing by 3 amino acids in humans). CGRP1 is traditionally considered the primary CGRP in the central and peripheral nervous system, while CGRP2 is mainly in the enteric nervous system.

The Constitution of the Empire of Japan was enacted on November 29, 1890. It was a form of mixed constitutional and absolute monarchy. The Emperor of Japan was legally the supreme leader, and the Cabinet were his followers. The Prime Minister would be elected by a Privy Council. In reality, the Emperor was head of state but the Prime Minister was the actual head of government. Class distinctions were mostly eliminated during modernization to create a representative democracy. The samurai lost their elite status as the only class with military privileges. However, during the Meiji period, most leaders in Japanese society (politics, business and military) were ex-samurai or descendants of samurai. The 1889 Meiji Constitution made relatively small concessions to civil rights and parliamentary mechanisms. Party participation was recognized as part of the political process. The Emperor shared his authority and gave rights and liberties to his subjects. It provided for the Imperial Diet (Teikoku Gikai), composed of a popularly elected House of Representatives with a very limited franchise of male citizens who were over twenty-five years of age and paid fifteen yen in national taxes (approximately 1% of the population). The House of Peers was composed of nobility and imperial appointees. A cabinet was responsible to the Emperor and independent of the legislature. The Diet could approve government legislation and initiate laws, make representations to the government, and submit petitions to the Emperor. The Meiji Constitution lasted as the fundamental law until 1947.

In 1990, Maroon et al. published the first microsurgical approach to far lateral disc herniations in the lumbar spine and in 2007, they published the case of Golfer's Stroke from Vertebral Artery Dissection. Further groundbreaking publications include the use of fish oil as an anti-inflammatory and alternative to nonsteroidal drugs for discogenic pain (2006); a unifying, immunoexcitotoxicity hypothesis for chronic traumatic encephalopathy (2011); and the possible use of a restricted calorie ketogenic diet for the treatment of glioblastoma multiforme (2013). In 2021, he began collaborating with Dr. Pravat Mandal on research utilizing magnetic resonance spectroscopy to assess glutathione deficiency—the brain's most abundant antioxidant—as a potential biomarker for the early diagnosis of Alzheimer's and Parkinson's diseases. In 2023, he was appointed to the board of directors of Syncromune, a biotechnology company developing novel immunotherapies that integrate cryosurgery and checkpoint inhibitor drugs for the treatment of solid tumors. In 2025, he and his colleagues received a research grant from the Chuck Noll Foundation to investigate glutathione deficiency in the brains of former National Football League (NFL) players and former Navy SEALs. Dr. Maroon is also an advocate for the use of hyperbaric oxygen therapy in the treatment of post-concussion syndrome, post-traumatic stress disorder (PTSD), long COVID, stroke, and spinal cord injury. He has authored several publications on these topics.

=== Casting === Upon the series order announcement, Peters, Ramos, Pope, and Ashton Kutcher were cast in starring roles. Rebecca Hall was cast as part of the main cast by the time the series had begun production. In February 2025, it was reported that Isabella Rossellini had joined the cast in a recurring role. In July 2026, it was reported that the entire cast had been released so the actors can pursue other projects.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network